New Risk Score Predicts Mortality for Atrial Fibrillation Patients Undergoing Transcatheter Aortic Valve Replacement

Mount Sinai researchers develop new risk stratification tool to optimize patient care and outcomes after TAVR

Major bleeding reduced in patients having non-cardiac surgery

The drug tested, tranexamic acid (TXA), was given to patients at risk of bleeding or vascular complications. The study found that TXA did not increase deep vein clotting known as VTE, heart attack, non-hemorrhagic stroke, or other major vascular complication in the 30 days after surgery.
In the study, half of 9,535 patients in 22 countries were randomly assigned TXA, half placebo. Patients were 45 years or older (average age 69 years); 44% of them were female.